P199 TREATMENT DISCONTINUATION, FLARES, AND HOSPITALIZATIONS AMONG BIOLOGIC-NAïVE PATIENTS WITH IBD OVER THE FIRST YEAR OF TREATMENT: A “REAL-WORLD” COMPARATIVE EFFECTIVENESS STUDY OF VEDOLIZUMAB VERSUS INFLIXIMAB

The clinical effectiveness of vedolizumab (VDZ), a gut-selective anti-integrin antibody used to treat patients with moderately-to-severely active IBD, was compared with that of the tumor necrosis factor antagonist infliximab (IFX).